Bardet-Biedl Syndrome Pipeline Summary

DelveInsight’s, “Bardet-Biedl Syndrome - Pipeline Insight, 2026” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Bardet-Biedl Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Bardet-Biedl Syndrome: Understanding

Bardet-Biedl Syndrome: Overview

Bardet-Biedl syndrome (BBS) is a rare autosomal recessive multisystem ciliopathy caused by pathogenic variants in genes encoding proteins essential for primary cilia structure and function. First described independently by Georges Bardet and Arthur Biedl, BBS is characterized by key clinical features including rod-cone retinal dystrophy, early-onset obesity with hyperphagia, postaxial polydactyly, renal abnormalities, hypogonadism and genital anomalies, and neurodevelopmental or cognitive impairment. Clinical manifestations vary substantially between and within families and may evolve throughout life. Diagnostic criteria have been progressively refined to integrate clinical and molecular genetic findings, with recent consensus recommendations and diagnostic algorithms providing simplified frameworks for clinical application. A major therapeutic advance was the FDA approval of setmelanotide (Imcivree), the first targeted pharmacotherapy for BBS, with subsequent expansion of its indication to younger pediatric patients.

Bardet-Biedl syndrome is inherited primarily through an autosomal recessive pattern and is associated with pathogenic variants across multiple BBS-related genes encoding proteins involved in the basal body, centrosome, and primary cilium. The BBSome, a multi-protein complex comprising several BBS proteins, regulates the selective trafficking of receptors such as the melanocortin-4 and leptin receptors within cilia, thereby contributing to appetite control and energy homeostasis, while other BBS proteins act as chaperonin-like factors that support BBSome assembly. BBS1 is the most frequently implicated gene, followed by BBS10, although the contribution of individual genes varies across populations. Classical biallelic variants in a single gene remain the predominant inheritance mechanism, while oligogenic or modifier effects may influence disease penetrance and severity in some families. Founder effects have also been reported in several genetically isolated populations, resulting in regionally increased prevalence.

Bardet-Biedl syndrome is a primary nonmotile ciliopathy caused by impaired ciliary biogenesis, intraflagellar transport, and receptor trafficking. Although primary cilia are widely distributed throughout the body, disease manifestations predominantly affect tissues that depend heavily on ciliary signaling, including the hypothalamus, kidneys, retina, and developing limbs. In the hypothalamus, defective BBSome-mediated trafficking disrupts leptin receptor localization on POMC neurons, weakening leptin signaling and downstream ?-MSH–MC4R activation, which contributes to severe early-onset hyperphagia and obesity that is often poorly responsive to conventional lifestyle interventions and provides the rationale for MC4R agonist therapy with setmelanotide. In the kidneys, impaired ciliary function in tubular epithelial cells disrupts tubulogenesis and mechanosensory signaling, leading to structural abnormalities that may progress to chronic kidney disease and, in severe cases, kidney failure. In the retina, defective ciliary transport in photoreceptors causes progressive rod-cone dystrophy, typically beginning with childhood night blindness and advancing to peripheral and central visual field loss and severe visual impairment.

Patients with suspected Bardet-Biedl syndrome should undergo clinical assessment and molecular genetic testing, with diagnosis based on established combinations of major and minor clinical features; genetic testing is recommended to support treatment eligibility, counseling, and family planning. Multigene next-generation sequencing is preferred, while broader sequencing may be considered when results are inconclusive. Negative or uncertain genetic findings do not exclude BBS, and variant classifications should be periodically reassessed. Baseline and ongoing evaluations should include ophthalmologic testing to monitor retinal disease, renal imaging and kidney-function assessment, metabolic and endocrine screening, cardiac evaluation, and developmental and neuropsychological assessment in children. Regular surveillance and specialist referral should be tailored to individual clinical findings and disease progression.

Setmelanotide (Imcivree), an MC4R agonist, is the first and only FDA-approved therapy for BBS-associated obesity, reducing hyperphagia and body weight by targeting the underlying melanocortin pathway defect. Management is multidisciplinary, combining tailored dietary, behavioral, and physical activity interventions with selective consideration of bariatric surgery. Renal disease requires blood pressure and kidney-function monitoring, appropriate RAAS inhibition, and nephrology care, while BBS-associated retinal dystrophy is managed primarily with low-vision support and rehabilitation, with investigational gene therapies such as AXV-101 in early development. Endocrine and metabolic complications, including hypogonadism, diabetes, dyslipidemia, liver disease, and thyroid dysfunction, should be managed with individualized hormone replacement and guideline-based therapies.

"Bardet-Biedl Syndrome- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bardet-Biedl Syndrome pipeline landscape is provided which includes the disease overview and Bardet-Biedl Syndrome treatment guidelines. The assessment part of the report embraces, in depth Bardet-Biedl Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bardet-Biedl Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Bardet-Biedl Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Bardet-Biedl Syndrome.

Bardet-Biedl Syndrome Emerging Drugs Chapters

This segment of the Bardet-Biedl Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bardet-Biedl Syndrome Emerging Drugs

AXV101: Axovia Therapeutics

AXV-101 is an investigational gene therapy designed to address the underlying genetic cause of BBS1-associated retinal degeneration by delivering a functional copy of the BBS1 gene directly to retinal cells. Using a viral vector, the therapy aims to restore production of the BBS1 protein, preserve photoreceptor function, and potentially slow or prevent further vision loss. Axovia is evaluating AXV-101 through subretinal administration in patients with biallelic BBS1 mutations and retinal degeneration, with initial clinical studies focused on assessing its safety, tolerability, and therapeutic potential. According to company’s pipeline the drug is in Phase I stage of it’s development for the treatment of Bardet-Biedl Syndrome.

Further product details are provided in the report……..

Bardet-Biedl Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Bardet-Biedl Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Bardet-Biedl Syndrome
• There are approx. 3+ key companies which are developing the therapies for Bardet-Biedl Syndrome. The companies which have their Bardet-Biedl Syndrome drug candidates in the most advanced stage, i.e. Phase I include, Axovia Therapeutics.

• Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Bardet-Biedl Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bardet-Biedl Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Bardet-Biedl Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bardet-Biedl Syndrome drugs.

Bardet-Biedl Syndrome Report Insights

• Bardet-Biedl Syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Bardet-Biedl Syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Bardet-Biedl Syndrome drugs?
• How many Bardet-Biedl Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bardet-Biedl Syndrome?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bardet-Biedl Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Bardet-Biedl Syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Avoxia Therapeutics
• MeiraGTx

Key Products

• AXV-101
• AAV8-RK-BBS10